Elmisol®, Levamisole HCl 5, 10, 25 and 50 mg

  • Product

    Elmisol, Levamisole HCl, 5, 10, 25 and 50 mg coated tablets

  • Authorisation

    Orphan Drug Designation EU/3/05/324

  • Active ingredient

    Levamisole 5, 10, 25 and 50 mg (as Levamisole HCl)

  • Indication

    Steroid-sensitive nephrotic syndrome

  • Storage condition

    Below 25 ⁰C

Elmisol (levamisole HCl) is prescribed for the treatment of steroid-sensitive nephrotic syndrome (SSNS) in children.

Elmisol is available in four strengths: 5, 10, 25 and 50 mg. The tablets are increasing in size (minitabs of 5, 6, 7 and 8 mm).

Legal status

Elmisol is an unlicensed medicine in the Netherlands. The Dutch Health Care Inspectorate (IGJ) has given permission for the supply.

Availability for (Hospital) Pharmacies

In France, Elmisol has an ATU-status. Distribution to hospital pharmacies in France is carried out by Laboratoire Intsel Chimos, INRESA Pharma and Laboratoire Cevidra.

In the United Kingdom, (hospital) pharmacies that require Elmisol can contact Idis.

(Hospital) Pharmacies that would like to know more about the availability of this product outside these countries are welcome to contact us via our contact form. If you have ordered Elmisol with us before, please our order form to place a new order.

Publications

ACE Pharmaceuticals has cooperated in the creation of publications about Levamisole. An overview with links to these publications is available on the website of ACE Pharmaceuticals.